Drug Profile
Research programme: superoxide dismutase mimetics - Rocket
Alternative Names: INO-6001; INO-6002Latest Information Update: 09 Jan 2018
Price :
$50
*
At a glance
- Originator Inotek Pharmaceuticals
- Class Small molecules
- Mechanism of Action Superoxide dismutase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Age-related macular degeneration; Diabetic retinopathy
Most Recent Events
- 04 Jan 2018 Rocket Pharmaceuticals merged with Inotek Pharmaceuticals and the combined company was named Rocket Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA